|
|
|
|
|
Teisinis statusas
Patentas galioja
| (51) | INT.CL. | A61K 31/4439 | (2006.01) |
| A61K 31/496 | (2006.01) | ||
| A61K 31/47 | (2006.01) | ||
| A61P 17/00 | (2006.01) | ||
| A61P 17/02 | (2006.01) | ||
| A61P 17/06 | (2006.01) | ||
| A61K 9/00 | (2006.01) |
| (11) | Patento numeris | 3579837 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 18751042.5 |
| Europos patento paraiškos padavimo data | 2018-02-12 | |
| (97) | Europos patento paraiškos paskelbimo data | 2019-12-18 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2023-06-07 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/US2018/017810 |
| Data | 2018-02-12 |
| (87) | Numeris | WO 2018/148653 |
| Data | 2018-08-16 |
| (30) | Numeris | Data | Šalis |
| 201762457929 P | 2017-02-12 | US |
| (72) |
TANG-LIU, Diane , US
DEVRIES, Gerald, Woodrow , US
|
| (73) |
AiViva Biopharma, Inc. ,
848 North Rainbow Boulevard, Suite 2654, Las Vegas, NV 89107,
US
|
| (54) | AXITINIB, NINTEDANIB OR LENVATINIB FOR THE TREATMENT OF ROSACEA AND ATOPIC DERMATITIS |
| AXITINIB, NINTEDANIB OR LENVATINIB FOR THE TREATMENT OF ROSACEA AND ATOPIC DERMATITIS |